Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

2.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
3.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

4.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.

Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.

5.

Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.

Sailer V, Charpentier A, Dietrich J, Vogt TJ, Franzen A, Bootz F, Dietrich D, Schroeck A.

PLoS One. 2018 Feb 9;13(2):e0192742. doi: 10.1371/journal.pone.0192742. eCollection 2018.

6.

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer VW, Robinson BD, Park K, Cyrta J, Tagawa ST, Kossai M, Fontugne J, Kim R, Sigaras A, Rao R, Pancirer D, Faltas B, Bareja R, Molina AM, Nanus DM, Rajappa P, Souweidane MM, Greenfield J, Emde AK, Robine N, Elemento O, Sboner A, Demichelis F, Beltran H, Rubin MA, Mosquera JM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00038. Epub 2017 Jun 14.

7.

Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM.

Cancer. 2018 Mar 1;124(5):1008-1015. doi: 10.1002/cncr.31173. Epub 2017 Dec 19.

PMID:
29266381
8.

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA, Rickman DS.

Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). pii: a001487. doi: 10.1101/mcs.a001487. Epub 2017 May 3.

9.

Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.

Sailer V, Gevensleben H, Dietrich J, Goltz D, Kristiansen G, Bootz F, Dietrich D.

PLoS One. 2017 Jun 15;12(6):e0179412. doi: 10.1371/journal.pone.0179412. eCollection 2017.

10.

On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.

Sailer V, Pauli C, Merzier EC, Mosquera JM, Beltran H, Rubin MA, Rao RA.

Anticancer Res. 2017 Apr;37(4):1569-1573.

11.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

12.

SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.

Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, Ponnala L, Ittmann M, Chinnaiyan AM, Sboner A, Chen Y, Rubin MA, Barbieri CE.

Cancer Cell. 2017 Mar 13;31(3):436-451. doi: 10.1016/j.ccell.2017.02.004.

13.

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.

Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, Franzen A, Dietrich J, Kristiansen G, Bootz F, Schröck A, Dietrich D.

Clin Epigenetics. 2017 Feb 2;9:12. doi: 10.1186/s13148-017-0317-7. eCollection 2017.

14.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, Kristiansen G.

J Mol Diagn. 2017 Jan;19(1):107-114. doi: 10.1016/j.jmoldx.2016.08.008. Epub 2016 Dec 8.

PMID:
27939865
15.

Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.

Meller S, VAN Ellen A, Gevensleben H, Bicker A, Hankeln T, Gorr TA, Sailer V, Dröge F, Schröck F, Bootz F, Schröck A, Perner S, Dietrich D, Kristiansen G.

Anticancer Res. 2016 Dec;36(12):6235-6241.

PMID:
27919941
16.

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.

Oncotarget. 2016 Nov 29;7(48):79943-79955. doi: 10.18632/oncotarget.13161.

17.

PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.

Sailer V, Holmes EE, Gevensleben H, Goltz D, Dröge F, de Vos L, Franzen A, Schröck F, Bootz F, Kristiansen G, Schröck A, Dietrich D.

Oncotarget. 2016 Nov 15;7(46):75827-75838. doi: 10.18632/oncotarget.12417.

18.

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.

Holmes EE, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G, Dietrich D.

Clin Epigenetics. 2016 Sep 26;8:104. doi: 10.1186/s13148-016-0270-x. eCollection 2016.

19.

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.

Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D.

Epigenetics. 2016 Dec;11(12):871-880. Epub 2016 Sep 30.

20.

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.

Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F.

Int J Mol Sci. 2016 Sep 23;17(10). pii: E1618. doi: 10.3390/ijms17101618.

21.

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.

Goltz D, Holmes EE, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G, Dietrich D.

Oncotarget. 2016 Aug 16;7(33):53309-53320. doi: 10.18632/oncotarget.10786.

22.

Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report.

Stein J, Latz S, Ellinger J, Hauser S, Sailer V, Oelmann-Avendano J, Marx C, Brossart P, Wolf D, Müller SC.

Urol Int. 2016;97(3):369-372. Epub 2016 Apr 2.

PMID:
27035919
23.

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer.

Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):487-96. doi: 10.1016/j.tranon.2015.11.004.

24.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

25.

Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

Sailer V, Lüders C, Kuhn W, Pelzer V, Kristiansen G.

Virchows Arch. 2015 Jul;467(1):67-70. doi: 10.1007/s00428-015-1766-z. Epub 2015 Apr 8.

PMID:
25850754
26.

Glutathione S-transferase-pi protein expression in prostate cancer--not always a useful diagnostic tool.

Sailer V, Eberhard HL, Stephan C, Wernert N, Perner S, Jung K, Dietel M, Bubendorf L, Kristiansen G.

Histopathology. 2015 Oct;67(4):577-9. doi: 10.1111/his.12671. Epub 2015 Apr 9. No abstract available.

PMID:
25684637
27.

Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia.

Meller S, Bicker A, Montani M, Ikenberg K, Rostamzadeh B, Sailer V, Wild P, Dietrich D, Uhl B, Sulser T, Moch H, Gorr TA, Stephan C, Jung K, Hankeln T, Kristiansen G.

Virchows Arch. 2014 Oct;465(4):419-27. doi: 10.1007/s00428-014-1646-y. Epub 2014 Aug 30.

PMID:
25172328
28.

Histopathological screening for prostate carcinoma: is a benign biopsy a negative biopsy?

Sailer V, Kristiansen G.

APMIS. 2014 Aug;122(8):690-8. doi: 10.1111/apm.12291. Review.

PMID:
25046199
29.

Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.

Holmes EE, Jung M, Meller S, Leisse A, Sailer V, Zech J, Mengdehl M, Garbe LA, Uhl B, Kristiansen G, Dietrich D.

PLoS One. 2014 Apr 3;9(4):e93933. doi: 10.1371/journal.pone.0093933. eCollection 2014.

30.

Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition.

Dietrich D, Uhl B, Sailer V, Holmes EE, Jung M, Meller S, Kristiansen G.

PLoS One. 2013 Oct 14;8(10):e77771. doi: 10.1371/journal.pone.0077771. eCollection 2013.

31.

Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?

Sailer V, Stephan C, Wernert N, Perner S, Jung K, Dietel M, Kristiansen G.

Histopathology. 2013 Jul;63(1):50-6. doi: 10.1111/his.12116. Epub 2013 May 13.

PMID:
23668398
32.

[Massive ovarian edema in a 13-year-old girl].

Sailer V, Huss S, Wardelmann E, Müller AM.

Pathologe. 2013 Nov;34(6):563-5. doi: 10.1007/s00292-013-1762-5. German.

PMID:
23649810
33.

Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis.

Ribback S, Calvisi DF, Cigliano A, Sailer V, Peters M, Rausch J, Heidecke CD, Birth M, Dombrowski F.

J Hepatol. 2013 Jun;58(6):1147-56. doi: 10.1016/j.jhep.2013.01.013. Epub 2013 Jan 21.

PMID:
23348238
34.

Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience.

Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA, Schulz K, Steinmetz I, Dombrowski F, Dölken G, Krüger WH.

Ann Hematol. 2012 Jul;91(7):1081-9. doi: 10.1007/s00277-012-1406-5. Epub 2012 Jan 17.

PMID:
22249208
35.

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.

Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, Herrmann T, Roth A, Chick J, Brock K, Albert D, Philip PA.

Invest New Drugs. 2007 Aug;25(4):385-90. Epub 2007 Mar 16.

PMID:
17364234
36.

Detoxification enzymes following intrastriatal kainic acid.

Cohen MR, Ramchand CN, Sailer V, Fernandez M, McAmis W, Sridhara N, Alston C.

Neurochem Res. 1987 May;12(5):425-9.

PMID:
2884584
37.

Free radical scavenging systems and the effect of peroxide damage in aged human skin fibroblasts.

Gutman RL, Cohen MR, McAmis W, Ramchand CN, Sailer V.

Exp Gerontol. 1987;22(6):373-8.

PMID:
3440484
38.

Superoxide dismutase activity in fibroblasts from patients with schizophrenia.

Cohen MR, Sailer V, McAmis B, Jenkins P.

Biol Psychiatry. 1986 Mar;21(3):322-4. No abstract available.

PMID:
3947714
39.

[Modification of the plasma concentration of individual lipoprotein density classes through starvation and carbohydrate-rich diet].

Sailer VS, Patsch J, Braunsteiner H.

Acta Med Austriaca. 1974;2(1):55-60. German. No abstract available.

PMID:
4377195
40.

[A RARE CASE OF SURVIVAL IN RUPTURE OF A GIANT SPLENIC CYST].

SAILER V.

Kinderarztl Prax. 1963 Oct;31:439-48. German. No abstract available.

PMID:
14128386
41.

[Lateral diverticulum of the hypopharynx].

KOLIHOVA E, VYHNANEK L, SAILER V.

Cesk Rentgenol. 1960 Feb;14:49-52. Czech. No abstract available.

PMID:
14410706

Supplemental Content

Loading ...
Support Center